Ukraine-US Security Deal Set to Be Signed, Says Zelensky
- The Inflation Reduction Act of 2022 is a landmark United States federal law that aims to lower healthcare costs, address climate change, and raise taxes on large corporations.
- The Act represents a compromise between the initial, more expansive "Build Back Better" plan and the realities of a narrowly divided Congress.
- Such as, the Congressional Budget Office estimated that the Act would reduce the deficit by $300 billion over the next ten years.
The Inflation Reduction Act of 2022
Table of Contents
The Inflation Reduction Act of 2022 is a landmark United States federal law that aims to lower healthcare costs, address climate change, and raise taxes on large corporations. President Joe Biden signed the bill into law on August 16, 2022, marking a notable legislative achievement for his administration.
The Act represents a compromise between the initial, more expansive “Build Back Better” plan and the realities of a narrowly divided Congress. It focuses on three core pillars: reducing healthcare costs, investing in climate and energy security, and ensuring that the largest corporations pay their fair share.
Such as, the Congressional Budget Office estimated that the Act would reduce the deficit by $300 billion over the next ten years. CBO Report
Healthcare Provisions
The Inflation Reduction Act directly addresses healthcare costs, especially prescription drug prices. It empowers Medicare to negotiate the prices of certain high-cost prescription drugs, a power previously prohibited by law.
Prior to the Act, Medicare was largely prevented from using its purchasing power to negotiate lower drug prices, leading to considerably higher costs for beneficiaries and the program itself. The law phases in drug price negotiation over several years, starting with a limited number of drugs and expanding over time.
As of January 1, 2026, Medicare will begin negotiating prices for 20 drugs covered under medicare Part D and Part B. CMS Fact Sheet
Climate and Energy Security Investments
The Inflation Reduction Act allocates approximately $369 billion to address climate change and bolster energy security. These investments encompass a wide range of initiatives, including tax credits for renewable energy production, incentives for energy efficiency improvements, and funding for climate resilience projects.
A key component of the climate provisions is the extension and expansion of tax credits for solar, wind, and other renewable energy sources. these credits aim to accelerate the transition to a clean energy economy and reduce greenhouse gas emissions.The Act also provides funding for the development of clean energy technologies, such as carbon capture and storage.
The Department of Energy estimates that the Act’s investments will reduce greenhouse gas emissions by roughly 40% below 2005 levels by 2030. DOE Inflation Reduction Act Page
Tax Provisions and Corporate Minimum Tax
To finance the spending provisions of the Act, the Inflation Reduction Act imposes new taxes, primarily on large corporations. A central element is a 15% minimum tax on corporations with over $1 billion in annual profits. This minimum tax aims to ensure that profitable corporations pay a baseline level of tax, even if they utilize deductions and credits to reduce their tax liability.
Prior to the Act, some large corporations where able to pay little or no federal income tax despite significant profits. The 15% minimum tax seeks to address this issue and increase tax revenue from these companies. The law also increases funding for the Internal Revenue Service (IRS) to improve tax enforcement.
The Joint Committee on Taxation estimates that the corporate minimum tax will generate approximately $315 billion in revenue over ten years. JCT Publications
legal Challenges and Implementation
The Inflation Reduction Act has faced legal challenges from various groups, primarily concerning the constitutionality of certain provisions. Challenges have focused on the authority of Congress to delegate power to the Executive Branch, particularly regarding drug price negotiation.
Several lawsuits were filed shortly after the Act’s enactment, arguing that the drug price negotiation provisions violate the Fifth Amendment’s Takings clause and the non-delegation doctrine. As of January 25, 2026, these cases are ongoing in various federal courts.
On February 21, 2024, the U.S. District Court for the Southern District of Ohio dismissed a lawsuit challenging the drug price negotiation provisions,finding that the plaintiffs lacked standing. Reuters Report on Court Ruling